Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.42 |
| ▸ | PPARG | P37231 | 1/20 | 0.40 |
| ▸ | PPARA | Q07869 | 1/20 | 0.40 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.39 |
| ▸ | KMO | O15229 | 2/20 | 0.39 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.39 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.38 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | CXCR3 | P49682 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1989472 | 0.90 | POLB (0.47) | SIGMAR1CHRM4POLBKDM4EALDH1A1 | |
| SCHEMBL1974828 | 0.89 | S1PR1 (0.49) | HRH3SIGMAR1POLBS1PR1S1PR5 | |
| SCHEMBL1974749 | 0.82 | SIGMAR1 (0.49) | SIGMAR1POLBKDM4EMAPTALDH1A1 | |
| SCHEMBL12604006 | 0.81 | SIGMAR1 (0.40) | HRH3PPARGPPARASIGMAR1CHRM4 | |
| SCHEMBL1751581 | 0.81 | HDAC4 (0.44) | SIGMAR1CHRM4S1PR1S1PR5KDM4E | |
| Water SCHEMBL2512481 | 0.81 | SIGMAR1 (0.47) | SIGMAR1POLBKDM4EMAPTALDH1A1 | |
| SCHEMBL3016371 | 0.80 | POLB (0.47) | SIGMAR1CHRM4POLBKDM4EMAPT | |
| Hydrochloric Acid SCHEMBL4092844 | 0.77 | SIGMAR1 (0.47) | SIGMAR1S1PR1S1PR5KDM4ENPC1 | |
| SCHEMBL5777725 | 0.75 | SIGMAR1 (0.54) | SIGMAR1S1PR1S1PR5KDM4EALDH1A1 | |
| SCHEMBL3008719 | 0.72 | MEN1 (0.46) | SIGMAR1KDM4ERAB9AHTTCHRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8344161-B2 | Process for the preparation of pyrollidine-3-carboxylic acids | HOFFMANN-LA ROCHE INC. (US) | 2013-01-01 | — | — | US | claimed |
| CN-102245570-A | Process for the preparation of pyrollidine-3-carboxylic acids | HOFFMANN LA ROCHE | 2011-11-16 | — | — | CN | claimed |
| EP-2379500-A1 | PROCESS FOR THE PREPARATION OF PYROLLIDINE-3-CARBOXYLIC ACIDS | F. Hoffmann-La Roche AG (CH) | 2011-10-26 | — | — | EP | claimed |
| WO-2010069793-A1 | PROCESS FOR THE PREPARATION OF PYROLLIDINE-3-CARBOXYLIC ACIDS | F. HOFFMANN-LA ROCHE AG (CH) | 2010-06-24 | — | — | WO | claimed |
| US-20100152462-A1 | PROCESS FOR THE PREPARATION OF PYROLLIDINE-3-CARBOXYLIC ACIDS | HOFFMANN-LA ROCHE, INC. | 2010-06-17 | — | — | US | claimed |
| US-9346786-B2 | Pyrrolidine compounds | HOFFMANN-LA ROCHE INC. (US) | 2016-05-24 | — | — | US | disclosed |
| US-9346786-B2 | Pyrrolidine compounds | HOFFMANN-LA ROCHE INC. (US) | 2016-05-24 | — | — | US | disclosed |
| US-9346786-B2 | Pyrrolidine compounds | HOFFMANN-LA ROCHE INC. (US) | 2016-05-24 | — | — | US | disclosed |
| EP-2513084-B1 | PYRROLIDINE DERIVATIVES AS NK-3 RECEPTOR ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2015-07-22 | — | — | EP | disclosed |
| EP-2513084-B1 | PYRROLIDINE DERIVATIVES AS NK-3 RECEPTOR ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2015-07-22 | — | — | EP | disclosed |
| US-20130203728-A1 | PYRROLIDINE COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2013-08-08 | — | — | US | disclosed |
| US-20130203728-A1 | PYRROLIDINE COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2013-08-08 | — | — | US | disclosed |
| US-20110152233-A1 | PYRROLIDINE COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2011-06-23 | — | — | US | disclosed |
| US-20110152233-A1 | PYRROLIDINE COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2011-06-23 | — | — | US | disclosed |
| WO-2011073160-A1 | PYRROLIDINE DERIVATIVES AS NK - 3 RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2011-06-23 | — | — | WO | disclosed |
| WO-2010069793-A1 | PROCESS FOR THE PREPARATION OF PYROLLIDINE-3-CARBOXYLIC ACIDS | F. HOFFMANN-LA ROCHE AG (CH) | 2010-06-24 | — | — | WO | disclosed |
| WO-2010069793-A1 | PROCESS FOR THE PREPARATION OF PYROLLIDINE-3-CARBOXYLIC ACIDS | F. HOFFMANN-LA ROCHE AG (CH) | 2010-06-24 | — | — | WO | disclosed |
| US-20100152462-A1 | PROCESS FOR THE PREPARATION OF PYROLLIDINE-3-CARBOXYLIC ACIDS | HOFFMANN-LA ROCHE, INC. | 2010-06-17 | — | — | US | disclosed |
| US-20100152462-A1 | PROCESS FOR THE PREPARATION OF PYROLLIDINE-3-CARBOXYLIC ACIDS | HOFFMANN-LA ROCHE, INC. | 2010-06-17 | — | — | US | disclosed |
| US-20100152462-A1 | PROCESS FOR THE PREPARATION OF PYROLLIDINE-3-CARBOXYLIC ACIDS | HOFFMANN-LA ROCHE, INC. | 2010-06-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130203728-A1 | PYRROLIDINE COMPOUNDS | SLC6A3, OPRL1, OPRK1 | HRH3 235/4885PPARG 2495/4885PPARA 2359/4885 |
| US-20100152462-A1 | PROCESS FOR THE PREPARATION OF PYROLLIDINE-3-CARBOXYLIC ACIDS | PYCR1, PYGB, PCCA | HRH3 543/4885PPARG 1100/4885PPARA 916/4885 |
| US-20110152233-A1 | PYRROLIDINE COMPOUNDS | SLC6A3, OPRL1, OPRK1 | HRH3 235/4885PPARG 2495/4885PPARA 2359/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.